Institut Curie

Institut National De La Sante Et De La Recherche Medicale

Centre National De La Recherche Scientifique

Other

Nestec S.a.

Sorbonne Université

Institut Gustave Roussy

Centre National De La Recherche Scientifique-cnrs

Institut National De La Sante Et De La Recherche Medicale (inserm)

Institute Curie

Theravectys

Anosys, Inc., Institute Curie

Mnemo Therapeutics

Université Pierre Et Marie Curie

Inserm

Sebastian Amigorena

Eliane Piaggio

Genevieve Almouzni

Luigia Pace

Leticia Niborski

Christel Goudot

Laurence Zitvogel

Franck Perez

Armelle Regnault

Eduardo Schiffrin

Dominique Brassart

Joël Crouzet

Cécile Bauche

Kevin Burke Miller

Sandrine Moutel

Marc-Henri Stern

Olivier Dhellin

Olivier Jacques Lantz

Benjamin Sadacca

Dmitry Trubetskoy

Elodie Segura

Graça Raposo

Philippe Rameau

Gra&ccedil;a Raposo

Alexandre Houy

Sophie Agaugue

Joshua Waterfall

Lorenzo Tibaldi

Marianne Burbage

Yago Arribas De Sandoval

Klervi Even-Desrumaux

Antonela Merlotti Ippolito

Geneviève Almouzni

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically hinds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Immune cells defective for SUV39H1

The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Immunotherapy targeting tumor neoantigenic peptides

The present invention relates to an engineered immune cell defective for Suv39h1. Preferably, said engineered immune cell further comprises a genetically engineered antigen receptor that specifically binds a target antigen. The present invention also relates to a method for obtaining a genetically engineered immune cell comprising a step consisting in inhibiting the expression and/or activity of Suv39h1 in the immune cell; and further optionally comprising a step consisting in introducing in the said immune cell a genetically engineered antigen receptor that specifically binds to a target antigen. The invention also encompasses said engineered immune cell for their use in adoptive therapy, notably for the treatment of cancer.

Immune cells defective for Suv39h1

The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.

Anti-LSP1 antibody

The invention relates to the regulated expression of a chimeric antigen receptor (CAR) within a lentiviral vector. The CAR comprises a hook-binding domain that interacts with a hook, preferably encoded by the same lentiviral vector, which prevents proper processing and release of the CAR to the cell membrane. The invention encompasses vectors, methods of making the vectors, and methods of using them, including medicinal uses. The vectors can be used for administration to humans to induce immune responses and to treat cancers and tumors.

Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule

The present invention relates to methods and immunonutritional compositions for preventing or mitigating paralysis of the bone marrow, caused by a tumor or neoplasm, between cycles of and after anti-cancer therapy, thereby attaining a better efficacy of the treatment. More particularly, the present invention relates to methods and immunonutritional compositions that can transiently preventing or moderating, bone marrow paralysis or neutropenia of a subject tumor-induced apoptosis or necrosis or other cell damage such that the innate and adaptive immune functions and normal physiology of the bone marrow are preserved, at least in part, which, in turn, lead to (i) a better tolerance and increased efficacy to treatment; (ii) transient augmentation or enhancement of immunocompetence of the immune cell; and (iii) optimization of the effects of and increase of immunocompetence of the immune cell weakened due to paralysis of the bone marrow, caused by a tumor or neoplasm.

Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor

The object of the invention is a novel sensitization process for antigen-presenting cells, novel means for implementing the process and novel membrane vesicles possessing immunogenic potency. The invention relates in particular to texosomes (vesicles derived from tumor cells) and dexosomes (vesicles derived from dendritic cells loaded or not with antigens), and their use for the vectorization and presentation of antigens in vitro or in vivo as well as in methods or compositions for the treatment of cancers and infectious, parasitic or autoimmune diseases in particular.

Sensitization process for antigen-presenting cells and means for implementing the process

This invention relates to a method of preparing membrane vesicles from a biological sample, characterised in that it comprises at least one anion exchange and/or gel permeation chromatography treatment of the sample. The invention is used to prepare vesicles of varied origins and types, particularly from antigen presenting cells or tumoral cells. The invention also relates to the vesicles obtained in this way and their uses.

Method for preparing membrane vesicles

Growing community of inventors

Paris, France

Sebastian Amigorena